What International Genomics Consortium does

International Genomics Consortium (IGC) is a nonprofit medical research organization headquartered in Phoenix, Arizona, founded in 1999 to accelerate the translation of genomic discoveries into clinically actionable information for cancer and complex diseases. The organization operates as a translational research platform: it designs and delivers high-impact research programs in collaboration with academic medical centers (such as Virginia G. Piper Cancer Center and the Arizona Cancer Center), health systems (Banner Health, St. Joseph's Hospital, University Medical Center Tucson), industry partners, and nonprofit organizations. IGC's core work centers on building and maintaining large, clinically annotated biorepositories — most notably the Expression Project for Oncology (expO), launched in 2001, which has collected over 15,000 samples from approximately 4,000 cancer patients, and its founding role as the Biospecimen Core Resource and Tissue Source Site network for The Cancer Genome Atlas (TCGA), where it manages tissue collection, pathology evaluation, and nucleic acid extraction across 18 hospitals nationally.

IGC's technical platform combines standardized biospecimen collection protocols, biobanking infrastructure, next-generation sequencing, and clinical data annotation. Its products and capabilities include publicly accessible genomic datasets (the expO and TCGA repositories), the Paradigm Cancer Diagnostic (PCDx) comprehensive genomic profiling test (interrogating DNA mutations, copy number variations, chromosomal changes, and mRNA expression at 5,000x depth with 72 therapeutic associations), and spin-out diagnostic platforms including LungVantage (a blood-based lung cancer detection assay with a 4-hour turnaround). IGC has also incubated multiple commercial ventures — the Molecular Profiling Institute (acquired by Caris Diagnostics in 2007, developer of Target Now, Mammostrat, and CardioEvaluatR), Paradigm and Viomics (acquired by Exact Sciences in March 2020), and Cirrus Bio (acquired by Maverix Medical in March 2024).

IGC is funded primarily through federal contracts and grants from the National Institutes of Health (notably NCI and NHGRI, including a $6.6M initial BCR grant in 2006 and approximately $59M in NIH contracts secured in 2010 for TCGA expansion) alongside donations from foundations and local government entities including Maricopa County, the City of Phoenix, and the Flinn Foundation. The organization employs 11-50 staff and shares the Phoenix Bioscience Center with TGen. Its go-to-market is partnership-driven rather than commercial sales: IGC distributes biospecimens, data access, and research services through direct research collaborations and contractual agreements, with TCGA data made freely available to the global research community without intellectual property restrictions.

Name

International Genomics Consortium

Legal name

International Genomics Consortium

Website

https://intgen.org

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

International Genomics Consortium is a Phoenix-based nonprofit medical research organization founded in 1999 that builds standardized cancer biorepositories and genomic datasets, serving the NIH and academic medical centers through translational research collaborations and diagnostic spin-outs.

Ownership category

akta.pro rank

Product category

Genomic Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

akta.pro secondary industries

Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Genomic research services
• Biospecimen biobanking
• Cancer genomics research
• Translational research support
• Molecular diagnostics development

Headquarters

HQ city

Phoenix

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. NIH/Government Research Grants and Contracts: IGC receives major federal contracts from the National Institutes of Health, including a $21.4 million contract for developing a national tissue-collection network and a $37.5 million contract for managing TCGA's Biospecimen Core Resource. Additional grants include $6.6 million initial BCR grant and $27.3 million in grant funding from University of Michigan Health System for Paradigm.
2. Nonprofit Donations and Foundation Support: IGC receives funding from foundations and donors including Maricopa County, City of Phoenix, Flinn Foundation, and other supporters for research initiatives and mission-aligned programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

IGC operates as a nonprofit translational genomics research organization that provides rigorously collected biospecimens, clinically annotated genomic datasets, and biobanking services to support cancer and complex disease research. It serves as the founding Biospecimen Core Resource for The Cancer Genome Atlas (TCGA) and operates the Expression Project for Oncology (expO), one of the first publicly accessible biorepositories linking cancer biospecimens with genomic data and clinical outcomes. The organization funds its mission primarily through NIH research grants and foundation donations, and has spun out commercial diagnostic ventures including Paradigm (PCDx), Viomics (LungVantage), and the Molecular Profiling Institute (Target Now, Mammostrat, CardioEvaluatR).

Product overview

International Genomics Consortium (IGC) is a nonprofit medical research organization that operates primarily as a biobanking and research infrastructure provider rather than a product company. Its core offerings include the Expression Project for Oncology (expO), which maintains a publicly accessible biorepository of cancer biospecimens and genomic data, and its role as the founding Biospecimen Core Resource for The Cancer Genome Atlas (TCGA) project. IGC has spun out several diagnostic companies including Paradigm (offering the PCDx comprehensive genomic profiling test), Viomics (developer of the LungVantage blood-based lung cancer assay), and contributed to the formation of the Molecular Profiling Institute (now Caris Life Sciences, offering Target Now, Mammostrat, and CardioEvaluatR diagnostic panels). These spin-off entities provide the commercial diagnostic products while IGC focuses on translational research support, biobanking services, and research collaborations.

Differentiator

Problem solved

Functional benefit

Products and services

• Expression Project for Oncology (expO) A national biospecimen repository and publicly accessible genomic dataset launched in 2001 that links cancer biospecimens with standardized genomic data and clinical outcomes to accelerate translational oncology research. Annotated data is available via the Genomic Expression Omnibus (GEO) and specimens were provided to TCGA.
• TCGA Biospecimen Core Resource Services A research service under which IGC operates as the founding Biospecimen Core Resource and Tissue Source Site network for The Cancer Genome Atlas, managing tissue collection from 18 hospitals nationwide, pathology evaluation, and nucleic acid extraction for genomic analysis to deliver comprehensive genomic "blueprints" of cancer types for the research community.
• Biorepository Services Access to rigorously collected biospecimens, clinically annotated datasets, and genomic analyses across multiple complex diseases, supporting investigators in generating, testing, and refining hypotheses to accelerate translational research.
• Paradigm Cancer Diagnostic (PCDx) A comprehensive genomic profiling test developed by Paradigm (an IGC spin-off) that analyzes DNA mutations, copy number variations, chromosomal changes, and mRNA gene expression to identify targeted, personalized treatment options for cancer patients.
• LungVantage A blood-based assay developed by Viomics for the early detection of lung and other cancers; validated as a fully automated, highly multiplexed assay with a 4-hour average turnaround time.
• Target Now A late-stage cancer panel developed by the Molecular Profiling Institute to guide targeted therapy selection based on genomic profiling of tumors.
• Mammostrat An early-stage breast cancer prognostic test that provides risk assessment information to guide treatment decisions.
• CardioEvaluatR A cardiovascular disease management panel providing genomic and proteomic profiling for cardiovascular health assessment.

Quantifiable outcome

• 25% of late-stage cancer patients treated using Paradigm Cancer Diagnostic (PCDx) targeted recommendations remained in remission, with additional 25% showing better progression-free survival versus standard of care
• +1 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Maverix MedicalcoreStrategic or Co-development Partner · 29 March 2024Cirrus Bio, co-founded by IGC founders David Mallery and Scott Morris, was acquired by Maverix Medical to form the foundation for a lung cancer diagnostics platform. IGC co-founders now lead Maverix Dx division focused on diagnostic solutions for lung cancer.
• Exact SciencescoreStrategic or Co-development Partner · 3 March 2020Paradigm and Viomics (both IGC-supported spin-offs) were acquired by Exact Sciences in March 2020. Paradigm offers comprehensive genomic profiling for advanced cancer patients, while Viomics focuses on blood-based assays for early cancer detection including the LungVantage assay.
• Indiana University Melvin and Bren Simon Cancer CenterminorStrategic or Co-development Partner · 15 May 2014IU cancer researchers partnered with Paradigm (IGC spin-off) for a clinical trial testing genomic sequencing in triple negative breast cancer. The trial used Paradigm's comprehensive genomic profiling to guide treatment decisions for 130 women.
• University of Michigan Health SystemcoreStrategic or Co-development Partner · 16 August 2012IGC partnered with University of Michigan to form Paradigm as a nonprofit joint venture for advanced DNA diagnostics. UMHS provided $27.3 million in grant funding and clinical expertise. Paradigm was established to bring next-generation molecular profiling to oncology patients nationally.
• Virginia G. Piper Cancer Center at Scottsdale HealthcarecoreStrategic or Co-development Partner · 22 June 2011Scottsdale Healthcare has been a keystone partner of IGC since its formation. The center serves as a Tissue Source Site providing cancer tissue samples under standardized conditions and collecting clinical outcome data for TCGA and other IGC research initiatives.
• Arizona Cancer Center (University of Arizona)coreStrategic or Co-development Partner · 22 June 2011The Arizona Cancer Center serves as a Tissue Source Site contributing cancer tissue samples and clinical data to IGC's biorepository. The collaboration brings together Tucson and Phoenix campuses of University of Arizona for comprehensive coverage.
• National Cancer Institute (NCI)coreStrategic or Co-development Partner · 1 January 2006IGC serves as founding Biospecimen Core Resource (BCR) and Tissue Source Site (TSS) network for The Cancer Genome Atlas (TCGA) project, jointly funded by NCI and NHGRI. IGC manages tissue collection from 18 hospitals nationwide and processes samples for genomic analysis.
• AmeriPathminorChannel Partner/ Reseller/ Distributor · 27 October 2005AmeriPath, one of the leading anatomic pathology laboratory companies in the U.S., served as the principal distribution channel for Molecular Profiling Institute's advanced tests. AmeriPath provided Series B funding and enhanced access to a wider patient base.
• Translational Genomics Research Institute (TGen)coreStrategic or Co-development PartnerIGC played a foundational role in the formation of TGen, which is now an affiliate of City of Hope. TGen and IGC share headquarters at the Phoenix Bioscience Center. TGen assists in genomic analysis while IGC manages the Biospecimen Core Resource for TCGA.
• Caris Life Sciences (formerly Molecular Profiling Institute)coreStrategic or Co-development PartnerIGC helped launch the Molecular Profiling Institute, which developed the flagship tumor profiling service that became a key component of Caris Life Sciences' testing. MPI developed products including Target Now, Mammostrat, and CardioEvaluatR. Caris Diagnostics combined with MPI in 2007.
• Vivia OncologyminorStrategic or Co-development PartnerVivia Oncology is a biotech company focused on high-throughput drug development to discover and optimize small-molecule inhibitors targeting novel oncogenic pathways, representing IGC's continued involvement in oncology research ecosystem.
• National Human Genome Research Institute (NHGRI)coreStrategic or Co-development PartnerNHGRI jointly funds and manages TCGA with NCI. IGC serves as the BCR for this initiative that has produced comprehensive genomic blueprints for dozens of cancer types.

Scale indicators9 records

Recent moves9 records

Expansion highlights5 records

Emerging players

• Personalis: Genomics company specializing in comprehensive genomic profiling and immuno-oncology biomarker discovery. Comparable technology stack to IGC's genomic profiling work for clinical research.
• Caris Life Sciences: Originated from IGC's Molecular Profiling Institute spin-off and now a leading molecular diagnostics company offering tumor profiling services (Target Now). Directly comparable as the commercial evolution of IGC's research infrastructure.
• Tempus Labs: AI-driven precision medicine company offering molecular profiling, multi-omics data analysis, and clinical trial matching. Overlaps with IGC's genomic data and biospecimen services for oncology research.
• Guardant Health: Precision oncology company focused on liquid biopsy and blood-based genomic testing. Comparable to IGC's Viomics spin-off (LungVantage) and broader translational research in blood-based cancer detection.

Broad incumbents

• Foundation Medicine: Molecular profiling company providing comprehensive genomic sequencing of tumors for oncology patients. Operates a much broader commercial infrastructure that overlaps with IGC's biospecimen and genomic profiling capabilities.
• Exact Sciences: Public diagnostics company that acquired Paradigm and Viomics (both IGC spin-offs). Operates in colorectal cancer screening and advanced oncology diagnostics with much greater scale than IGC.
• BioReference Laboratories: Large commercial clinical laboratory providing molecular and genetic diagnostics across oncology and other specialties. Comparable as a broader-scale lab services provider than IGC's specialty focus.

Others

• National Cancer Institute (NCI): Federal cancer research agency that has funded IGC's TCGA BCR role and provides ongoing grant support. A key sponsor and ecosystem participant rather than direct competitor.

Direct peers

• Translational Genomics Research Institute (TGen): Nonprofit genomics research institute sharing IGC's Phoenix Bioscience Center headquarters and co-founding IGC. Performs genomic analysis for cancer and complex diseases, directly comparable in translational research mission.
• The Jackson Laboratory: Nonprofit biomedical research institution operating large-scale mouse model and human biospecimen repositories for translational research. Directly comparable as a nonprofit biorepository provider for the research community.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/in/dmallery
• Instagraminstagram.com/intgen

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about International Genomics Consortium